Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Tolvaptan

Brand: JinarcĀ®
NICE TA: 358
Indication: Autosomal dominant polycystic kidney disease (NICE TA358)
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Tolvaptan is recommended as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency only if:
- they have chronic kidney disease stage 2 or 3 at the start of treatment
- there is evidence of rapidly progressing disease and
- the company provides it with the discount agreed in the patient access scheme.

NHS England is the commissioner of dialysis and kidney transplants, hyponatraemia and other endocrine uses.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA358 - Tolvaptan for treating autosomal dominant polycystic kidney disease

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red